Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

The recommendations place an emphasis on the utility of ultrasound-guided placement to enhance safety.

Researchers Develop Recommendations for Hyaluronic Acid Filler Placement in Cases of Hollowness, Volume Deficits

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

Ruxolitinib Cream Shows Strong Efficacy in Max-Use Pediatric Trial

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

The 5% dosage showed a 6-fold increase in normal hair count after just 5 weeks.

 ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Congenital malalignment syndrome is a nail disorder caused by the lateral rotation of the nail matrix.

The Dx and Rx of Congenital Malalignment Syndrome in Children

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Provider and Patient Considerations for Prurigo Nodularis Treatment

Video content above is prompted by the following:

6. What  kind of clinical and practical considerations would you suggest when selecting a treatment for treating patients with prurigo nodularis? How might a treatment approach differ based on severity of disease?

7. How would you characterize patient awareness regarding these treatment options, and do you have any tips for talking to patients about the importance of systemic treatment?

Prurigo nodularis presents diagnostic challenges due to its overlapping symptoms with other pruritic conditions and the lack of specific diagnostic tests. Clinicians often rely on clinical evaluation and patient history to differentiate it from other conditions. Certain patient subtypes, such as those with atopic dermatitis, may exhibit increased prevalence. Distinguishing prurigo nodularis involves assessing the characteristic nodules, chronic itch, and potential underlying systemic conditions. A thorough examination and consideration of differential diagnoses are crucial for accurate identification and management of this condition.

Melodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.

New Systemic Treatments for Prurigo Nodularis

5. Two systemic treatments are now FDA-approved for prurigo nodularis: dupilumab and nevolizumabnemolizumab. Can you briefly discuss these two 2 agents, including similarities/differences as well as efficacy and safety?

Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.

Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

2. What are some of the challenges of diagnosing prurigo nodularis? Are there certain patient subtypes with increased prevalence?

3. How do you distinguish prurigo nodularis from other pruritic conditions?

Melodie Young, MSN, A/GNP-C, discusses how diagnosing prurigo nodularis can be challenging due to its similarity to other pruritic conditions, and highlights the importance of recognizing key features and patient subtypes with increased prevalence to accurately differentiate it from conditions like eczema and psoriasis.

The upcoming year is poised to bring significant advancements in dermatologic treatments, with 3 highly anticipated Prescription Drug User Fee Act (PDUFA) dates on the horizon. These therapies address pressing unmet needs in dermatology and promise to enhance patient care.

First, dupilumab (Dupixent) has the potential to become the first targeted therapy for chronic spontaneous urticaria in over a decade. Backed by strong data from the LIBERTY-CUPID clinical trials, Dupixent offers hope for patients struggling with uncontrolled itching and hives.

Next, prademagenezamikeracel (pz-cel) may revolutionize care for patients with recessive dystrophic epidermolysis bullosa, a rare and debilitating condition. The FDA's acceptance of Abeona Therapeutics’ resubmitted Biologics License Application puts this innovative gene therapy one step closer to addressing unmet needs in wound healing and pain management.

Finally, roflumilast foam 0.3% (Zoryve) offers a steroid-free, easy-to-apply option for treating scalp and body psoriasis. Results from the ARRECTOR phase 3 trial highlight its potential to clear plaques and relieve symptoms in hair-bearing and other hard-to-treat areas.

We want to hear from you. Which of these PDUFA dates are you most excited about, and why? Cast your vote in our poll below and share your thoughts with the 

Dupilumab (Dupixent; Sanofi) for chronic spontaneous urticaria

Pz-cel (prademagenezamikeracel) (Abeona Therapeutics) for recessive dystrophic epidermolysis bullosa

Roflumilast foam 0.3% (Zoryve; Arcutis Biotherapeutics) for scalp and body psoriasis

Want to share more of your insights and perspectives with us? Email our team at 

Dupixent (dupilumab) sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (CSU). News release. Regeneron. November 15, 2024. Accessed January 3, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic

Abeona Therapeutics announces FDA accepts and grants Priority Review for pz-cel biologics license application (BLA). News release. Abeona Therapeutics. November 27, 2023. Accessed January 3, 2025. 

https://investors.abeonatherapeutics.com/press-releases/detail/268/abeona-therapeutics-announces-fda-accepts-and-grants

Arcutis submits supplemental new drug application for ZORYVE (roflumilast) foam to the FDA for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over. News release. Arcutis Biotherapeutics, Inc. July 23, 2024. Accessed January 3, 2025. 

https://www.arcutis.com/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-foam-to-the-fda-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over/

Significant advancements in dermatologic treatments are anticipated with three upcoming Prescription Drug User Fee Act (PDUFA) dates. Dupilumab (Dupixent) could become the first targeted therapy for chronic spontaneous urticaria in over a decade, offering hope for patients with uncontrolled symptoms. Prademagenezamikeracel (pz-cel) may revolutionize care for recessive dystrophic epidermolysis bullosa, addressing unmet needs in wound healing and pain management. Roflumilast foam 0.3% (Zoryve) provides a steroid-free option for treating scalp and body psoriasis, showing promise in clearing plaques and relieving symptoms.

Share your insights and anticipation with us.

Polls 

POLL: Which Anticipated Drug Approval/PDUFA Date Are You Most Looking Forward to in 2025?

From Clinic to Practice: Translating AD Trial Data

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

Amar Davé, MD, FAAP;

Articles

Latest Updated Articles